Close
Smartlab Europe
Achema middle east

News

Daiichi Sankyo begins phase 1 trial in Japan for nafamostat inhalation formulation to treat Covid-19

Daiichi Sankyo Company, Limited announced that it has initiated in Japan a first-in-human phase 1 trial for nafamostat inhalation formulation (DS-2319), which is being developed as a potential medicine for the treatment of the novel coronavirus infectious disease (hereinafter,...

Cold Chain Technologies Partners with B Medical Systems

Cold Chain Technologies announced that it is partnering with B Medical Systems, a Luxembourg-based manufacturer and global distributor of medical refrigeration and durable vaccine cold-chain technology. The partnership expands Cold Chain Technologies' portfolio to include hand-carry transport solutions as...

Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing

Ajinomoto Bio-Pharma Services Cold Chain Technologies Partners with B Medical Systems , a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a manufacturing agreement expansion with AstraZeneca to include drug product manufacturing. This agreement expands...

Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Companys COVID-19 Vaccine Candidate

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to make available up to 220 million doses of its single-shot COVID-19 vaccine candidate...

Humanigen Reports Positive Phase 3 Topline Results Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19

Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced positive topline results from its Phase 3 clinical trial evaluating the efficacy and safety...

Foresee Pharma Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS

Foresee Pharmaceuticals Co., Ltd. announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with associated Acute Respiratory Distress Syndrome (ARDS). Dr....

GSK to support manufacture of Novavax COVID-19 vaccine

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »